• Herick Ulisses de Oliveira, Rafaela Silva Dos Santos, MaltaIago Henrique SilvaIHSSciences of Motricity Institute, Federal University of Alfenas, Alfenas, Brazil., José Phellipe Pinho, AlmeidaAna Flávia SantosAFSDepartment of Physiology, Federal University of Minas Gerais, Belo Horizonte, Brazil., Carlos Arterio Sorgi, Ana Paula Ferranti Peti, Gabriela Santos Xavier, ReisLuciana Maria DosLMDSciences of Motricity Institute, Federal University of Alfenas, Alfenas, Brazil., Lúcia Helena Faccioli, CruzJader Dos SantosJDSDepartment of Physiology, Federal University of Minas Gerais, Belo Horizonte, Brazil., Enio Ferreira, and Giovane Galdino.
• Sciences of Motricity Institute, Federal University of Alfenas, Alfenas, Brazil.
• J Pain. 2020 Jul 1; 21 (7-8): 820-835.

AbstractTranscutaneous electrical nerve stimulation (TENS) promotes antinociception by activating the descending pain modulation pathway and consequently releasing endogenous analgesic substances. In addition, recent studies have shown that the endocannabinoid system controls pain. Thus, the present study investigated the involvement of the endocannabinoid system in TENS-induced antinociception of cancer pain using a cancer pain model induced by intraplantar (i.pl.) injections of Ehrlich tumor cells in male Swiss mice. Low- and high-frequency TENS was applied for 20 minutes to the mice's paws, and to investigate the involvement of the endocannabinoid system were used the N-(peperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pitazole-3-carboixamide (AM251), a cannabinoid CB1 receptor antagonist and (5Z,8Z,11Z,14Z)-5,8,11,14-eicosatetraenyl-methylester phosphonofluoridic acid (MAFP), an inhibitor of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase, injected by via i.pl., intrathecal (i.t.), and intradorsolateral periaqueductal gray matter (i.dl.PAG). Furthermore, liquid chromatography-tandem mass spectrometry, western blot, and immunofluorescence assays were used to evaluate the endocannabinoid anandamide levels, cannabinoid CB1 receptor protein levels, and cannabinoid CB1 receptor immunoreactivity, respectively. Low- and high-frequency TENS reduced the mechanical allodynia induced by Ehrlich tumor cells and this effect was reversed by AM251 and potentiated by MAFP at the peripheral and central levels. In addition, TENS increased the endocannabinoid anandamide levels and the cannabinoid CB1 receptor protein levels and immunoreactivity in the paw, spinal cord, and dorsolateral periaqueductal gray matter. These results suggest that low- and high-frequency TENS is effective in controlling cancer pain, and the endocannabinoid system is involved in this effect at both the peripheral and central levels. PERSPECTIVE: TENS is a nonpharmacological strategy that may be used to control cancer pain. Identification of a new mechanism involved in its analgesic effect could lead to the development of clinical studies as well as an increase in its application, lessening the need for pharmacological treatments.Copyright © 2019 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

33 keywords...

hide…